Damora Therapeutics (DMRA) Shares Outstanding (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Shares Outstanding (Entity) data on file, last reported at $34.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 2493.79% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.3 million (up 2493.79% YoY) and the FY2025 annual result came in at $1.6 million, up 21.29% from the prior year.
• Shares Outstanding (Entity) improved to $34.3 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $34.3 million in Q1 2026 to a low of $1.3 million in Q3 2024.
• A 5-year average of $18.0 million and a median of $25.6 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) plunged 95.38% — and 2026, when it soared 2493.79%.
• Tracing DMRA's Shares Outstanding (Entity) over 5 years: stood at $25.7 million in 2022, then grew by 5.69% to $27.1 million in 2023, then sank by 95.14% to $1.3 million in 2024, then advanced by 21.29% to $1.6 million in 2025, then jumped by 2047.29% to $34.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $34.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.